Scarica l'app Stockscreener
14.26
0.97%
-0.14
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$14.40
Aprire:
$14.47
Volume 24 ore:
347.11K
Relative Volume:
1.02
Capitalizzazione di mercato:
$263.99M
Reddito:
$1.93M
Utile/perdita netta:
$-7.96M
Rapporto P/E:
-0.00404
EPS:
-3530.8178
Flusso di cassa netto:
$-36.78M
1 W Prestazione:
+0.49%
1M Prestazione:
-17.09%
6M Prestazione:
+57.13%
1 anno Prestazione:
+84.48%
Intervallo 1D:
$14.03
$14.94
Intervallo di 1 settimana:
$13.50
$14.94
Portata 52W:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Nome
Avalo Therapeutics Inc
Settore
Industria
Telefono
410-522-8707
Indirizzo
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
14.26 | 266.58M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-05 | Iniziato | TD Cowen | Buy |
| 2025-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-25 | Iniziato | Jefferies | Buy |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-28 | Iniziato | Piper Sandler | Overweight |
| 2025-02-21 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-10-24 | Iniziato | H.C. Wainwright | Neutral |
| 2024-04-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
Can Avalo Therapeutics Inc. outperform under higher oil pricesJuly 2025 PreEarnings & Low Risk High Win Rate Picks - mfd.ru
Is Avalo Therapeutics Inc. stock overvalued by current metricsJuly 2025 Final Week & Consistent Profit Trade Alerts - mfd.ru
How Avalo Therapeutics Inc. stock reacts to global recession fearsWeekly Stock Analysis & Free Risk Controlled Daily Trade Plans - mfd.ru
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa - Yahoo Finance
AVTX: Phase 2b LOTUS trial for AVTX-009 in HS nears Q2 data, targeting rapid phase 3 and new indications - TradingView
What analysts say about Avalo Therapeutics Inc. stockJuly 2025 Breakouts & AI Driven Price Forecasts - mfd.ru
Dow Update: Will Avalo Therapeutics Inc outperform the market in YEARRate Hike & Long-Term Capital Growth Ideas - baoquankhu1.vn
Avalo Therapeutics shares jump as Guggenheim starts coverage with buy - MSN
Avalo Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Biotech firm Avalo will stream two investor talks in February - Stock Titan
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Benzinga
Guggenheim Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on Avalo Therapeutics (AVTX) with - GuruFocus
Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating By Investing.com - Investing.com Australia
Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating - Investing.com
Guggenheim Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - MarketBeat
Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy - Investing.com UK
Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy By Investing.com - Investing.com India
Avalo Therapeutics Completes Enrollment for AVTX-009 Trial - Intellectia AI
Avalo Therapeutics Highlights AVTX-009 Progress in HS - TipRanks
Aug Update: Is Avalo Therapeutics Inc in a bullish channelJuly 2025 Short Interest & Expert Curated Trade Setups - baoquankhu1.vn
Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study - MSN
Patterns Watch: Is Avalo Therapeutics Inc a potential multi bagger2025 Top Gainers & Safe Entry Zone Tips - baoquankhu1.vn
Market Pulse: What is the long term forecast for Renovaro Inc stock2025 Geopolitical Influence & Comprehensive Market Scan Reports - baoquankhu1.vn
Gainers Report: Can Avalo Therapeutics Inc outperform under higher oil pricesJuly 2025 Price Swings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $32.71 Consensus Price Target from Analysts - Defense World
Market Wrap: What is the target price for DXLG stock2025 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 38.2% in December - MarketBeat
Avalo Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of trial data By Investing.com - Investing.com South Africa
Avalo Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of trial data - Investing.com Nigeria
Avalo Therapeutics' (AVTX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aug Summary: What analysts say about Avalo Therapeutics Inc stockTreasury Yields & Detailed Earnings Play Alerts - baoquankhu1.vn
Avalo Therapeutics (AVTX) Gets 'Buy' Rating Reiteration from HC Wainwright | AVTX Stock News - GuruFocus
Retail Trends: Is Avalo Therapeutics Inc stock a safe investment in uncertain markets2025 Winners & Losers & Reliable Momentum Entry Alerts - Bộ Nội Vụ
Insider Sell: Is Avalo Therapeutics Inc stock positioned for digital transformationJuly 2025 Technicals & AI Optimized Trading Strategy Guides - Bộ Nội Vụ
Will Avalo Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Retail & Step-by-Step Trade Execution Guides - Улправда
Will Avalo Therapeutics Inc. stock split attract more investorsEarnings Overview Summary & Risk Controlled Swing Alerts - Улправда
Moving Averages: Will Avalo Therapeutics Inc. stock split attract more investorsWall Street Watch & Safe Entry Trade Signal Reports - Улправда
Is Avalo Therapeutics Inc. stock positioned well for digital economy2025 Risk Factors & High Accuracy Swing Trade Signals - Улправда
Avalo Therapeutics Reports Q3 2025 Financial Results - MSN
Avalo Therapeutics Files $750 Million Mixed Shelf - marketscreener.com
Avalo Therapeutics files for mixed shelf of up to $750 millionSEC filing - marketscreener.com
What margin trends mean for Avalo Therapeutics Inc. stockSwing Trade & Technical Pattern Based Signals - Улправда
Aug Momentum: Will Avalo Therapeutics Inc. stock benefit from AI adoptionAnalyst Downgrade & Accurate Intraday Trading Signals - ulpravda.ru
Is Avalo Therapeutics Inc. stock attractive after correctionPortfolio Risk Summary & Stepwise Entry and Exit Trade Signals - Улправда
Why analysts remain bullish on Avalo Therapeutics Inc. stockSwing Trade & Fast Gaining Stock Strategy Reports - ulpravda.ru
Options Flow: What margin trends mean for Avalo Therapeutics Inc stockGap Down & Weekly Sector Rotation Insights - Bộ Nội Vụ
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV), Avalo Therapeutics (AVTX) and Lifestance Health Group (LFST) - The Globe and Mail
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Avalo Therapeutics Inc Azioni (AVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):